ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Economics"

  • Abstract Number: 0168 • ACR Convergence 2023

    What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment

    Nick Bansback1, Alex Tam2, Dafna Gladman3, Vathany Kulasingam4, Eldon Spackman5 and Vinod Chandran6, 1University of British Columbia, Vancouver, BC, Canada, 2Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 4Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, 5University of Calgary, Calgary, AB, Canada, 6Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Initiating treatment in patients with psoriasis (PsO) who have unrecognized Psoriatic arthritis (PsA) may slow disease progression and improve long-term outcomes. Several candidate biomarkers…
  • Abstract Number: 0169 • ACR Convergence 2023

    Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective

    Alejandro Figueroa-Lara1, Mary Ann Aure2 and Carmen Andalucia1, 1Werfen, San Diego, CA, 2Werfen, Chula Vista, CA

    Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
  • Abstract Number: 0173 • ACR Convergence 2023

    Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis

    Peter C. Taylor1 and Jenya Antonova2, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA

    Background/Purpose: For rheumatoid arthritis (RA) American College of Rheumatology (ACR) recommends the treating to target approach, starting with conventional synthetic antirheumatic drugs (DMARDs). ACR advises…
  • Abstract Number: 0242 • ACR Convergence 2023

    Venous Thromboembolism in Patients with Gout in the US

    Alka Mithal1, Maanek Sehgal1, Brian LaMoreaux2 and Gurkirpal Singh1, 1ICORE, Woodside, CA, 2Horizon Therapeutics, Deerfield, IL

    Background/Purpose: Venous thromboembolism (VTE), manifested by deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common medical problem with an estimated incidence of 1–2…
  • Abstract Number: 0335 • ACR Convergence 2023

    Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool

    Vladislav Tsaltskan1, Roel Baez2 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2UC San Diego Health, San Diego, CA

    Background/Purpose: Recruitment of study participants is challenging and can incur significant costs, particularly for studies of rheumatic disease or other rare conditions. Social media advertising…
  • Abstract Number: 0966 • ACR Convergence 2023

    The Burden of Oligoarticular Psoriatic Arthritis in the United States

    Abisola Olopoenia1, Ashley Martin2, Kate Orroth3, Cynthia Deignan4, Myriam Cordey5 and Dafna Gladman6, 1Cerner Enviza, North Kansas City, MO, 2BluePath Solutions, Los Angeles, CA, 3Amgen, Inc., Manhattan Beach, CA, 4Amgen, Inc., Agoura Hills, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
  • Abstract Number: 1286 • ACR Convergence 2022

    Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center

    Joad Eseddi1, DeAnne Carmichael2, Shannon Wishin3 and Puneet Bajaj2, 1UT Southwestern School of Medicine, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX, 3UT Southwestern Medical Centre, Dallas, TX

    Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
  • Abstract Number: 1312 • ACR Convergence 2022

    Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Leny Pearman4, jake Mathew4, Yamei Wang4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Waltham, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
  • Abstract Number: 1424 • ACR Convergence 2022

    Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

    Joanna KEDRA1, Lina El Houari1, Florence Tubach1, Benjamin granger1 and Bruno Fautrel2, 1Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, 2Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
  • Abstract Number: 1488 • ACR Convergence 2022

    Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study

    David Singer1, Philippe Thompson-Leduc2, Siyu Ma3, Deepshekhar Gupta4, Wendy Cheng5, Selvam Sendhil6, Manasvi Sundar6, Ella Hagopian5, Mei Sheng Duh7 and Sara Poston1, 1GSK, Philadelphia, PA, 2Analysis Group, Inc., Montréal, QC, Canada, 3GSK/Tufts Medical Center, Boston, MA, 4Analysis Group, Inc., Menlo Park, CA, 5Analysis Group, Inc., Boston, MA, 6Analysis Group, Inc., Los Angeles, CA, 7Analysis Group Inc, Boston, MA

    Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
  • Abstract Number: 2006 • ACR Convergence 2022

    Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan

    Kei Ikeda1, Yuko Kaneko2, Jayeshkumar Patel3, Toru Yamazaki4, Siran Fang3, Tsujita Yuki4 and Yutaka Kawahito5, 1Chiba University Hospital, Chiba, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3AbbVie, Inc., North Chicago, IL, 4AbbVie GK, Tokyo, Japan, 5Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan

    Background/Purpose: Substantial numbers of patients with RA receiving advanced therapies including biologics, biosimilars, and Janus kinase inhibitors do not achieve ACR50 responses and lack of…
  • Abstract Number: 2086 • ACR Convergence 2022

    Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus

    Ann E Clarke1, Manuel Ugarte-Gil2, Megan Barber3, John Hanly4, Murray Urowitz5, Yvan St. Pierre6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Sasha Bernatsky6, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan Mackay25, Guillermo Ruiz-Irastorza26, S. Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane Kamen32, Anca Askanase33, Bernardo Pons-Estel34 and Graciela Alarcón35, 1University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 7Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 10Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Raleigh Neurology Associates, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 24Amsterdam University Medical Centers, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 27Emory University, Atlanta, GA, 28Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 29University of California San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 35The University of Alabama at Birmingham, Oakland

    Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…
  • Abstract Number: 0059 • ACR Convergence 2022

    Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus

    Kenneth Kalunian1, Janice Ma2, Konrad Pisarczyk2, Richard Leff3, Kiruthi Palaniswamy4 and Li Long4, 1University of California San Diego, La Jolla, CA, 2Maple Health Group, LLC, New York, NY, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc., South San Francisco, CA

    Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…
  • Abstract Number: 0067 • ACR Convergence 2022

    Cost Per Responder in RA Patients Failing First Line Treatment

    Manuel Cardozo, Pharmalab PHL, Huixquilucan, Mexico

    Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…
  • Abstract Number: 0283 • ACR Convergence 2022

    The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)

    Nobuyuki Yajima1, Toshihiro Matsui2 and Shigeto Tohma3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2NHO Sagamihara National Hospital, Kanagawa, Japan, 3National Hospital Organization Tokyo National Hospital, Dallas, TX

    Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology